Verseon Corporation Verseon presents second anticoagulant candidate
November 15 2017 - 2:01AM
RNS Non-Regulatory
TIDMVSN
Verseon Corporation
15 November 2017
Press release November 15, 2017
Verseon Corporation
("Verseon" or the "Company")
Second anticoagulation candidate for clinical trials presented
at AHA 2017
Fremont, Calif.-Verseon, a technology-based pharmaceutical
company employing a computer-driven platform to develop a diverse
drug pipeline, presented a second development candidate for
clinical trials from its anticoagulation program at the American
Heart Association's (AHA) Scientific Sessions 2017, yesterday.
VE-2851 shows excellent efficacy paired with low bleeding risk in
preclinical testing and is expected to enter clinical trials in
2018.
The candidate potently inhibits thrombin and is highly selective
against a panel of related serine proteases. VE-2851 also shows
pharmacokinetics suitable for oral dosing and was well tolerated in
a 14-day dose-range finding study. In preclinical efficacy models
such as the arteriovenous shunt thrombosis model, the compound
displayed comparable efficacy to marketed anticoagulants. Similar
to Verseon's first development candidate VE-1902, which is expected
to enter phase I trials in early 2018, VE-2851 likewise potently
inhibits thrombosis, but does not disrupt platelet function. It
shows 30-40--fold weaker inhibition of thrombin-mediated platelet
activation in vitro and allows up to 5-fold higher maximum platelet
activation in vivo compared to current NOACs. This distinguishing
feature of Verseon's anticoagulants provides a biological rationale
for their improved hemostatic control and the resulting lower
bleeding risk observed in preclinical bleeding time tests.
"We are excited to have two drug candidates heading to the
clinic in 2018," said Dr. Anirban Datta, Verseon's Director of
Discovery Biology, who presented the results at the AHA conference.
"Both development candidates act as potent anticoagulants without
disrupting platelet function. This may allow them to become the
first anticoagulants suitable for long-term combination therapy
with antiplatelet drugs, achieving a significantly reduced risk of
both major adverse cardiovascular events and bleeding."
The full AHA abstract is available on the conference website and
will be published in Circulation. Dr. Datta's presentation will
also be featured in Thrombosis.TV, a leading destination for venous
and arterial thrombosis education, news, and expert opinion.
About Verseon's anticoagulation program
Verseon's potent, highly selective oral direct thrombin
inhibitors have shown excellent efficacy in multiple preclinical
studies, but do not disrupt platelet function. This unique feature
could explain the low bleeding risk of these precision
anticoagulants and makes them excellent candidates for use in
long-term combination anticoagulant-antiplatelet therapy. Two
development candidates are expected to enter clinical trials in
2018, one of which has also demonstrated very low renal clearance,
a highly desirable property for patients with impaired kidney
function.
About Verseon
Verseon Corporation (www.verseon.com, AIM: VSN) is a
technology-based pharmaceutical company that combines a
proprietary, computational drug discovery platform with a
comprehensive in-house chemistry and biology workflow to develop
novel therapeutics that are unlikely to be found using conventional
methods. The Company is applying its platform to a growing drug
pipeline and currently has four active drug programs in the areas
of anticoagulation, diabetic macular edema, hereditary angioedema,
and oncology. The anticoagulation program is scheduled to enter
phase I clinical trials in 2018.
-Ends-
For further information, please contact
Verseon Corporation www.verseon.com
+1 (510) 225
Tina Schlafly 9000
Cenkos Securities (NOMAD and
Joint Broker)
+44 (0) 20
Neil McDonald / Beth McKiernan 7397 8900
Cantor Fitzgerald Europe (Joint
Broker)
Marc Milmo / Phil Davies / +44 (0) 20
Callum Butterfield 7894 7000
Mirabaud Securities LLP (Joint
Broker)
+44 (0) 20
Peter Krens 7321 2508
For financial and business media enquiries, please contact
Buchanan Communications Ltd
(PR Advisers)
Henry Harrison-Topham / Jamie +44 (0) 20
Hooper 7466 5000
For trade and pharma media enquiries, please contact
Vane Percy & Roberts
+44 (0) 1737
Simon Vane Percy 821 890
Forward-Looking Statements
This press release contains forward-looking statements, which
are generally statements that are not historical facts.
Forward-looking statements can be identified by the words
"expects," "anticipates," "believes," "intends, " "estimates,"
"plans," "will," "outlook," and similar expressions.
Forward-looking statements are based on management's current plans,
estimates, assumptions, and projections, and speak only as of the
date they are made. We undertake no obligation to update any
forward-looking statement in light of new information or future
events, except as otherwise required by law. Forward-looking
statements involve inherent risks and uncertainties, most of which
are difficult to predict and are generally beyond our control.
Actual results or outcomes may differ materially from those implied
by the forward-looking statements as a result of the impact of a
number of factors.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRADDBDBSGBBGRX
(END) Dow Jones Newswires
November 15, 2017 02:01 ET (07:01 GMT)
Verseon (LSE:VSN)
Historical Stock Chart
From Apr 2024 to May 2024
Verseon (LSE:VSN)
Historical Stock Chart
From May 2023 to May 2024